BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 26045549)

  • 41. [Comparison of GnRH antagonist fixed protocol and GnRH agonists long protocol in infertile patients with normal ovarian reserve function in their first in vitro fertilization-embryo transfer cycle].
    Yang S; Chen XN; Qiao J; Liu P; Li R; Chen GA; Ma CH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):245-9. PubMed ID: 22781108
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Use of Utrogestan during controlled ovarian hyperstimulation in normally ovulating women undergoing in vitro fertilization or intracytoplasmic sperm injection treatments in combination with a "freeze all" strategy: a randomized controlled dose-finding study of 100 mg versus 200 mg.
    Zhu X; Ye H; Fu Y
    Fertil Steril; 2017 Feb; 107(2):379-386.e4. PubMed ID: 27865446
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Menstrual cycle synchronization, ovarian stimulation, and in vitro fertilization in olive baboons (Papio anubis): a prospective randomized study.
    Nyachieo A; Spiessens C; Chai DC; Mwenda JM; D'Hooghe TM
    Fertil Steril; 2009 Feb; 91(2):602-10. PubMed ID: 18328482
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of multiple dose GnRH antagonist and minidose long agonist protocols in poor responders undergoing in vitro fertilization: a randomized controlled trial.
    Tazegül A; Görkemli H; Ozdemir S; Aktan TM
    Arch Gynecol Obstet; 2008 Nov; 278(5):467-72. PubMed ID: 18335226
    [TBL] [Abstract][Full Text] [Related]  

  • 45. GnRH agonist trigger with intensive luteal phase support vs. human chorionic gonadotropin trigger in high responders: an observational study reporting pregnancy outcomes and incidence of ovarian hyperstimulation syndrome.
    Christopoulos G; Vlismas A; Carby A; Lavery S; Trew G
    Hum Fertil (Camb); 2016 Sep; 19(3):199-206. PubMed ID: 27662416
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Live birth rates after modified natural cycle compared with high-dose FSH stimulation using GnRH antagonists in poor responders.
    Lainas TG; Sfontouris IA; Venetis CA; Lainas GT; Zorzovilis IZ; Tarlatzis BC; Kolibianakis EM
    Hum Reprod; 2015 Oct; 30(10):2321-30. PubMed ID: 26307091
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Influence of Different Gonadotropin-releasing Hormone Agonist Administration Methods on Pregnancy Outcomes of Patients Undergoing In-vitro Fertilization-embryo Transfer.
    Wu L; Ren XL; Chen W; Huang B; Zhou YF; Jin L
    Curr Med Sci; 2019 Jun; 39(3):437-441. PubMed ID: 31209816
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparisons of different dosages of gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization.
    Hsieh YY; Chang CC; Tsai HD
    Taiwan J Obstet Gynecol; 2008 Mar; 47(1):66-74. PubMed ID: 18400585
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Comparison of GnRH agonists and antagonists in an ovular donation program].
    Saucedo de la Llata E; Moraga Sánchez MR; Batiza Reséndiz V; Santos Haliscak R; Galache Vega P; Hernández Ayup S
    Ginecol Obstet Mex; 2004 Feb; 72():53-6. PubMed ID: 15216901
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Stimulation of the young poor responder: comparison of the luteal estradiol/gonadotropin-releasing hormone antagonist priming protocol versus oral contraceptive microdose leuprolide.
    Shastri SM; Barbieri E; Kligman I; Schoyer KD; Davis OK; Rosenwaks Z
    Fertil Steril; 2011 Feb; 95(2):592-5. PubMed ID: 21074154
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.
    Hohmann FP; Macklon NS; Fauser BC
    J Clin Endocrinol Metab; 2003 Jan; 88(1):166-73. PubMed ID: 12519847
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Impact of controlled ovarian hyperstimulation delayed, which occurs after functionally pituitary downregulation by depot GnRH agonist, on the outcome of in vitro fertilization and embryo transfer].
    Ma QH; Li SW; Huang ZY; Han ZY; Qiu DS; Han DW
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Nov; 38(6):980-3. PubMed ID: 18095601
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Microdose gonadotropin-releasing hormone agonist flare-up protocol versus multiple dose gonadotropin-releasing hormone antagonist protocol in poor responders undergoing intracytoplasmic sperm injection-embryo transfer cycle.
    Kahraman K; Berker B; Atabekoglu CS; Sonmezer M; Cetinkaya E; Aytac R; Satiroglu H
    Fertil Steril; 2009 Jun; 91(6):2437-44. PubMed ID: 18555238
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Management of poor responders: can outcomes be improved with a novel gonadotropin-releasing hormone antagonist/letrozole protocol?
    Schoolcraft WB; Surrey ES; Minjarez DA; Stevens JM; Gardner DK
    Fertil Steril; 2008 Jan; 89(1):151-6. PubMed ID: 17482177
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Gonadotropin-releasing hormone agonist combined with a reduced dose of human chorionic gonadotropin for final oocyte maturation in fresh autologous cycles of in vitro fertilization.
    Shapiro BS; Daneshmand ST; Garner FC; Aguirre M; Thomas S
    Fertil Steril; 2008 Jul; 90(1):231-3. PubMed ID: 17981269
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Clinical application of gonadotropin-releasing hormone antagonist in Chinese women undergoing controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer].
    Chen SL; Yin MN; Sun L; Li H; Chen X; Song HD; He JX; Zhu L; Xing FQ
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 May; 27(5):588-90. PubMed ID: 17545062
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Corifollitropin alfa compared with follitropin beta in poor responders undergoing ICSI: a randomized controlled trial.
    Kolibianakis EM; Venetis CA; Bosdou JK; Zepiridis L; Chatzimeletiou K; Makedos A; Masouridou S; Triantafillidis S; Mitsoli A; Tarlatzis BC
    Hum Reprod; 2015 Feb; 30(2):432-40. PubMed ID: 25492411
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A novel protocol of ovulation induction with delayed gonadotropin-releasing hormone antagonist administration combined with high-dose recombinant follicle-stimulating hormone and clomiphene citrate for poor responders and women over 35 years.
    D'Amato G; Caroppo E; Pasquadibisceglie A; Carone D; Vitti A; Vizziello GM
    Fertil Steril; 2004 Jun; 81(6):1572-7. PubMed ID: 15193479
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose gonadotropin-releasing hormone agonist protocol for patients with a history of poor in vitro fertilization outcomes.
    Weitzman VN; Engmann L; DiLuigi A; Maier D; Nulsen J; Benadiva C
    Fertil Steril; 2009 Jul; 92(1):226-30. PubMed ID: 18675961
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Estradiol supplementation during the luteal phase of IVF-ICSI patients: a randomized, controlled trial.
    Serna J; Cholquevilque JL; Cela V; Martínez-Salazar J; Requena A; Garcia-Velasco JA
    Fertil Steril; 2008 Dec; 90(6):2190-5. PubMed ID: 18191847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.